Potential antidepressant properties of IDN 5491 (hyperforin- trimethoxybenzoate), a semisynthetic ester of hyperforin

European Neuropsychopharmacology

Volumn 15, Issue 2, 2005, Pages 211-218

  Cervo, Luigi ^a   Mennini, Tiziana ^a   Rozio, Marco ^a   Ekalle Soppo, Charlotte Blanche ^a   Canetta, Alessandro ^a   Burbassi, Silvia ^a   Guiso, Giovanna ^a   Pirona, Lorenza ^a   Riva, Antonella ^b   Morazzoni, Paolo ^b   Caccia, Silvio ^a   Gobbi, Marco ^a  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b INDENA S P A   (Italy)

Author keywords

Antidepressant like activity; Brain to plasma distribution ratio; Hypericum perforatum L. extracts; IDN 5491 (hyperforin trimethoxybenzoate); Rat

Indexed keywords

ANTIDEPRESSANT AGENT; DOPAMINE 2 RECEPTOR BLOCKING AGENT; ESTER DERIVATIVE; HYPERFORIN; HYPERICUM EXTRACT; IDN 5491; LIGAND; N [2 (2,3 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; SIGMA 1 OPIATE RECEPTOR; SULPIRIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; BLOOD LEVEL; BRAIN; CENTRAL NERVOUS SYSTEM; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DEPRESSION; DRUG POTENTIATION; EX VIVO STUDY; IN VITRO STUDY; MALE; MEASUREMENT; METABOLITE; NONHUMAN; PRIORITY JOURNAL; RAT; SWIMMING;

EID: 19944434259     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2004.07.004     Document Type: Article

References (49)

1. J.S. Aguilar, P.J. Salas, and E. De Robertis Cholinergic muscarinic receptor in synaptosomal membranes. Heterogeneity of binding sites for l-[3H]quinuclidinyl benzilate Mol. Pharmacol. 22 1982 304 309
2. S.K. Bhattacharya, A. Chakrabarti, and S.S. Chatterjee Activity profiles of two hyperforin-containing hypericum extracts in behavioral models Pharmacopsychiatry 31 Suppl. 1 1998 22 29
3. A. Biber, H. Fischer, A. Romer, and S.S. Chatterjee Oral bioavailability of hyperforin from hypericum extracts in rats and human volunteers Pharmacopsychiatry 31 Suppl. 1 1998 36 43
4. A.R. Bilia, M.C. Bergonzi, F. Morgenni, G. Mazzi, and F.F. Vincieri Evaluation of chemical stability of St. John's wort commercial extract and some preparations Int. J. Pharm. 213 2001 199 208
5. E Bombardelli, and P. Morazzoni Hypericum perforatum Fitoterapia 66 1995 43 68
6. E. Bombardelli, P. Morazzoni, and A. Riva IDN 5491 (Hyperforin trimethoxybenzoate): a new antidepressive drug Eur. Neuropsychopharmacol. 12 Suppl. 3 2002 S240
7. F. Borsini, A. Lecci, A. Mancinelli, V. D'Aranno, and A. Meli Stimulation of dopamine D-2 but not D-1 receptors reduces immobility time of rats in the forced swimming test: implication for antidepressant activity Eur. J. Pharmacol. 148 1988 301 307
8. V. Butterweck, A. Wall, U. Lieflander-Wulf, H. Winterhoff, and A. Nahrstedt Effects of the total extract and fractions of Hypericum perforatum in animal assays for antidepressant activity Pharmacopsychiatry 30 Suppl. 2 1997 117 124
9. V. Butterweck, A. Nahrstedt, J. Evans, S. Hufeisen, L. Rauser, J. Savage, B. Popadak, P. Ernsberger, and B.L. Roth In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs Psychopharmacology (Berl.) 162 2002 193 202
10. G. Calapai, A. Crupi, F. Firenzuoli, G. Inferrera, F. Squadrito, A. Parisi, G. De Sarro, and A. Caputi Serotonin, norepinephrine and dopamine involvement in the antidepressant action of Hypericum perforatum Pharmacopsychiatry 34 2001 45 49
11. G. Campiani, M. De Angelis, S. Armaroli, C. Fattorusso, B. Catalanotti, A. Ramunno, V. Nacci, E. Novellino, C. Grewer, D. Ionescu, T. Rauen, R. Griffiths, C. Sinclair, E. Fumagalli, and T. Mennini A rational approach to the design of selective substrates and potent nontransportable inhibitors of the excitatory amino acid transporter EAAC1 (EAAT3). new glutamate and aspartate analogues as potential neuroprotective agents J. Med. Chem. 44 2001 2507 2510
12. G. Campiani, S. Butini, F. Trotta, C. Fattorusso, B. Catalanotti, F. Aiello, S. Gemma, V. Nacci, E. Novellino, J.A. Stark, A. Cagnotto, E. Fumagalli, F. Carnovali, L. Cervo, and T. Mennini Synthesis and pharmacological evaluation of potent and highly selective D3 receptor ligands: inhibition of cocaine-seeking behavior and the role of dopamine D3/D2 receptors J. Med. Chem. 46 2003 3822 3839
13. L. Cervo, G. Grignaschi, and R. Samanin The role of the mesolimbic dopaminergic system in the desipramine effect in the forced swimming test Eur. J. Pharmacol. 178 1990 129 133
14. L. Cervo, M. Rozio, C.B. Ekalle-Soppo, G. Guiso, P. Morazzoni, and S. Caccia Role of hyperforin in the antidepressant-like activity of Hypericum perforatum extracts Psychopharmacology (Berl.) 164 2002 423 428
15. S.S. Chatterjee, S.K. Bhattacharya, M. Wonnemann, A. Singer, and W.E. Muller Hyperforin as a possible antidepressant component of hypericum extracts Life Sci. 63 1998 499 510
16. S.S. Chatterjee, M. Noldner, E. Koch, and C. Erdelmeier Antidepressant activity of Hypericum perforatum and hyperforin: the neglected possibility Pharmacopsychiatry 31 Suppl. 1 1998 7 15
17. S.S. Chatterjee, A. Biber, and C. Weibezahn Stimulation of glutamate, aspartate and gamma-aminobutyric acid release from synaptosomes by hyperforin Pharmacopsychiatry 34 Suppl. 1 2001 S11 S19
18. J.F. Cryan, A. Markou, and I. Lucki Assessing antidepressant activity in rodents: recent developments and future needs Trends Pharmacol. Sci. 23 2002 238 245
19. M. Dziedzicka-Wasylewska, W. Kolasiewicz, Z. Rogoz, W. Margas, and J. Maj The role of dopamine D2 receptor in the behavioral effects of imipramine-study with the use of antisense oligonucleotides J. Physiol. Pharmacol. 51 2000 401 409
20. C.A. Erdelmeier Hyperforin, possibly the major non-nitrogenous secondary metabolite of Hypericum perforatum L Pharmacopsychiatry 31 Suppl. 1 1998 2 6
21. C. Gambarana, P.L. Tolu, F. Masi, M. Rinaldi, D. Giachetti, P. Morazzoni, and M.G. De Montis A study of the antidepressant activity of Hypericum perforatum on animal models Pharmacopsychiatry 34 Suppl. 1 2001 S42 S44
22. M. Gobbi, and T. Mennini Is St John's wort a 'Prozac-like' herbal antidepressant? Trends Pharmacol. Sci. 22 2001 557 559
23. M. Gobbi, and T. Mennini A critical analysis of receptor binding studies W.E. Muller St. John's Wort and its Active Principles in Depression and Anxiety 2004 Birkhäuser Verlag Basel in press
24. M. Gobbi, S. Cavanus, A. Miari, and T. Mennini Effect of acute and chronic administration of buspirone on serotonin and benzodiazepine receptor subtypes in the rat brain: an autoradiographic study Neuropharmacology 30 1991 313 321
25. M. Gobbi, M.C. Regondi, M. Pompeiano, J.M. Palacios, and T. Mennini Differential effects of 5,7-dihydroxytryptamine-induced serotoninergic degeneration of 5-HT1A receptors and 5-HT uptake sites in the rat brain J. Chem. Neuroanat. 7 1994 65 73
26. M. Gobbi, F. Dalla Valle, C. Ciapparelli, L. Diomede, P. Morazzoni, L. Verotta, S. Caccia, L. Cervo, and T. Mennini Hypericum perforatum L. extract does not inhibit 5-HT transporter in rat brain cortex Naunyn-Schmiedeberg's Arch. Pharmacol. 360 1999 262 269
27. M. Gobbi, M. Moia, L. Pirona, P. Morazzoni, and T. Mennini In vitro binding studies with two Hypericum perforatum extracts-hyperforin, hypericin and biapigenin-on 5-HT6, 5-HT7, GABA(A)/benzodiazepine, sigma, NPY-Y1/Y2 receptors and dopamine transporters Pharmacopsychiatry 34 Suppl. 1 2001 S45 S48
28. M.A. Gonzales, T.N. Tozer, and D.T.T. Chang Non-linear tissue disposition salicyclic acid in rat brain J. Pharm. Sci. 64 1975 99 103
29. L.G. Guilhermano, L. Ortiz, M. Ferigolo, and H.M.T. Barros Commercially available Hypericum perforatum extracts do not decrease immobility of rats in the forced swimming test Prog. Neuro-Psychopharmacol. Biol. Psychiatry 28 2004 49 55
30. A.G. Gutierrez-Garcia, C.M. Contreras, J.L. Diaz-Meza, B. Bernal-Morales, J.F. Rodriguez-Landa, and M. Saavedra Intraaccumbens dopaminergic lesion suppresses desipramine effects in the forced swim test but not in the neuronal activity of lateral septal nucleus Prog. Neuro-Psychopharmacol. Biol. Psychiatry 27 2003 809 818
31. M.A. Hebert, G.A. Larson, N.R. Zahniser, and G.A. Gerhardt Age-related reductions in [3H]WIN 35,428 binding to the dopamine transporter in nigrostriatal and mesolimbic brain regions of the fischer 344 rat J. Pharmacol. Exp. Ther. 288 1999 1334 1339
32. P. Jenner, and C.D. Marsden Substituted benzamide drugs as selective neuroleptic agents Neuropharmacology 20 1981 1285 1293
33. J.H. Keller, M. Karas, W.E. Muller, D.A. Volmer, G.P. Eckert, M.A. Tawab, H.H. Blume, T. Dingermann, and M. Schubert-Zsilavecz Determination of hyperforin in mouse brain by high-performance liquid chromatography/tandem mass spectrometry Anal. Chem. 75 2003 6084 6088
34. G. Laakmann, C. Schule, T. Baghai, and M. Kieser St. John's wort in mild to moderate depression: the relevance of hyperforin for the clinical efficacy Pharmacopsychiatry 31 Suppl. 1 1998 54 59
35. K. Linde, and C.D. Mulrow St John's wort for depression (Cochrane Review) The Cochrane Library, Issue 3 2004 John Wiley & Sons, Ltd Chichester, UK
36. I. Lucki, A. Singh, and D.S. Kreiss Antidepressant-like behavioral effects of serotonin receptor agonists Neurosci. Biobehav. Rev. 18 1994 85 95
37. R.R. Matsumoto, W.D. Bowen, M.A. Tom, V.N. Vo, D.D. Truong, and B.R. De Costa Characterization of two novel sigma receptor ligands: antidystonic effects in rats suggest sigma receptor antagonism Eur. J. Pharmacol. 280 1995 301 310
38. K. Matsuno, T. Kobayashi, M.K. Tanaka, and S. Mita Sigma 1 receptor subtype is involved in the relief of behavioral despair in the mouse forced swimming test Eur. J. Pharmacol. 312 1996 267 271
39. T. Mennini, R. Bagnati, L. Cervo, and M. Gobbi Hyperforin does not inhibit brain serotonin uptake for inducing antidepressant-like activity in rats 15th Congress of the European College of Neuropsychopharmacology, Barcellona, Spain 2002
40. T. Mennini, D. Barone, and M. Gobbi In vivo interaction of premazepam with benzodiazepine receptors: relation to its pharmacological effects Psychopharmacology (Berl.) 86 1985 464 467
41. M. Modica, M. Santagati, S. Guccione, F. Russo, A. Cagnotto, M. Goegan, and T. Mennini Design, synthesis and binding properties of novel and selective 5-HT3 and 5-HT4 receptor ligands Eur. J. Med. Chem. 36 2001 287 301
42. A. Nahrstedt, and V. Butterweck Biologically active and other chemical constituents of the herb of Hypericum perforatum L Pharmacopsychiatry 30 Suppl. 2 1997 129 134
43. V.H. Nguyen, M. Kassiou, G.A. Johnston, and M.J. Christie Comparison of binding parameters of sigma 1 and sigma 2 binding sites in rat and guinea pig brain membranes: novel subtype-selective trishomocubanes Eur. J. Pharmacol. 311 1996 233 240
44. I. Panocka, M. Perfumi, S. Angeletti, R. Ciccocioppo, and M. Massi Effects of Hypericum perforatum extract on ethanol intake, and on behavioral despair: a search for the neurochemical systems involved Pharmacol. Biochem. Behav. 66 2000 105 111
45. R.D. Porsolt, G. Anton, N. Blavet, and M. Jalfre Behavioural despair in rats: a new model sensitive to antidepressant treatments Eur. J. Pharmacol. 47 1978 379 391
46. R.B. Rothman, N. Grieg, A. Kim, B.R. De Costa, K.C. Rice, F.I. Carroll, and A. Pert Cocaine and GBR12909 produce equivalent motoric responses at different occupancy of the dopamine transporter Pharmacol. Biochem. Behav. 43 1992 1135 1142
47. U. Simmen, J. Higelin, K. Berger-Buter, W. Schaffner, and K. Lundstrom Neurochemical studies with St. John's wort in vitro Pharmacopsychiatry 34 Suppl. 1 2001 S137 S142
48. P. Willner, R. Muscat, and M. Papp Chronic mild stress-induced anhedonia: a realistic animal model of depression Neurosci. Biobehav. Rev. 16 1992 525 534
49. P. Zanoli, M. Rivasi, C. Baraldi, and M. Baraldi Pharmacological activity of hyperforin acetate in rats Behav. Pharmacol. 13 2002 645 651